AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38232100 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular curriculums and normal physical activity routines)
Number of subjects: 250
Study 38232249 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance electroconvulsive therapy (M-ECT) with medication
Number of subjects: 56
Study 38232249 — intervention group
Group type: COMPARATOR
Intervention: Medication only
Number of subjects: 56
Study 38232336 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurable residual disease (MRD) detection using targeted next-generation sequencing (NGS) panel and droplet digital polymerase chain reaction (ddPCR)
Number of subjects: 266
Study 38232336 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD+ (positive measurable residual disease)
Number of subjects: 266
Study 38232336 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD+ patients with chronic GVHD
Number of subjects: 266
Study 38232336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff levels of MRD (0.1%, 0.3%, 0.5%)
Number of subjects: 266
Study 38232336 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive BM MRD
Number of subjects: 266
Study 38232336 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous complete remission (CCR)
Number of subjects: 266
Study 38232337 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology-tailored (HT) regimen
Number of subjects: 101
Study 38232337 — intervention group
Group type: COMPARATOR
Intervention: Standard (S) anthracycline + ifosfamide (AI) regimen
Number of subjects: 101
Study 38232341 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus paclitaxel (GEMPAX)
Number of subjects: 211
Study 38232341 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 211
Study 38232682 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented yogurt products
Number of subjects: 100
Study 38232682 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fermented milk products
Number of subjects: 100
Study 38232682 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention products (fermented and non-fermented)
Number of subjects: 100
Study 38232692 — intervention group
Group type: EXPERIMENTAL
Intervention: High BAT volume (≥20 mL)
Number of subjects: 0
Study 38232692 — intervention group
Group type: COMPARATOR
Intervention: Low BAT volume (<20 mL)
Number of subjects: 0
Study 38232698 — intervention group
Group type: EXPERIMENTAL
Intervention: Early time-restricted eating (eTRE) schedule (0800 to 1400)
Number of subjects: 16
Study 38232698 — intervention group
Group type: COMPARATOR
Intervention: Control eating schedule (0800 to 2000)
Number of subjects: 16
Study 38232714 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Impact Scale (SIS) version 3.0
Number of subjects: 158
Study 38232714 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 158
Study 38232714 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS score, age, and depression
Number of subjects: 158
Study 38232864 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological pain treatments
Number of subjects: 164
Study 38232864 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite scores from 4 days of ratings
Number of subjects: 164
Study 38233009 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 59
Study 38233017 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated symptoms of anxiety (HADS-A)
Number of subjects: 3815
Study 38233017 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated symptoms of depression (HADS-D)
Number of subjects: 3815
Study 38233017 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated symptoms of both anxiety and depression
Number of subjects: 3815
Study 38233017 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) and Health Status (HS)
Number of subjects: 3815
Study 38233049 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived injustice-targeted pain neuroscience education (PNE)
Number of subjects: 156
Study 38233049 — intervention group
Group type: COMPARATOR
Intervention: Biomedically focused pain education
Number of subjects: 156
Study 38233053 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 101008
Study 38233053 — intervention group
Group type: EXPERIMENTAL
Intervention: Open myomectomy
Number of subjects: 101008
Study 38233053 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 101008
Study 38233053 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 101008
Study 38233053 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency MRI-guided focused ultrasound surgery (MRgFUS)
Number of subjects: 101008
Study 38233053 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 101008
Study 38233053 — intervention group
Group type: EXPERIMENTAL
Intervention: Myomectomy
Number of subjects: 101008
Study 38233053 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS
Number of subjects: 101008
Study 38233075 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal cortisol production in patients with RA
Number of subjects: 28
Study 38233075 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-induced minimal disease activity (MDA) at 6 months
Number of subjects: 28
Study 38233075 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline morning cortisol levels
Number of subjects: 28
Study 38233075 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ACTH levels
Number of subjects: 28
Study 38233075 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline morning cortisol <13.9 nmol/L
Number of subjects: 28
Study 38233075 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised diurnal cortisol production
Number of subjects: 28
Study 38233075 — intervention group
Group type: EXPERIMENTAL
Intervention: Disturbed circadian cortisol rhythm at baseline
Number of subjects: 28
Study 38233083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised normal saline (NS)
Number of subjects: 300
Study 38233083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation with normal saline (NS)
Number of subjects: 300
Study 38233083 — intervention group
Group type: COMPARATOR
Intervention: No saline therapy
Number of subjects: 300
Study 38233280 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate sleep (maintenance of habitual bed/wake times)
Number of subjects: 65
Study 38233280 — intervention group
Group type: COMPARATOR
Intervention: Insufficient sleep (reduction in sleep of 1.5 hours relative to adequate sleep)
Number of subjects: 65
Study 38233280 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate sleep
Number of subjects: 65
Study 38233280 — intervention group
Group type: COMPARATOR
Intervention: Insufficient sleep
Number of subjects: 65
Study 38233512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative social adversity
Number of subjects: 537
Study 38233570 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 0
Study 38233575 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. 24 mg dexamethasone
Number of subjects: 31
Study 38233575 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 31
Study 38233586 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T cell therapy (axicabtagene ciloleucel)
Number of subjects: 0
Study 38233586 — intervention group
Group type: COMPARATOR
Intervention: standard of care (salvage chemotherapy followed by hematopoietic transplantation)
Number of subjects: 0
Study 38233592 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 year intensive lifestyle intervention
Number of subjects: 4402
Study 38233592 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (control)
Number of subjects: 4402
Study 38233608 — intervention group
Group type: EXPERIMENTAL
Intervention: DROP-IN + LaproFlex combination
Number of subjects: 10
Study 38233608 — intervention group
Group type: COMPARATOR
Intervention: Rigid laparoscopic probe
Number of subjects: 10
Study 38233608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence guidance
Number of subjects: 10
Study 38233784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballet-based dance programme (12 one-weekly sessions)
Number of subjects: 160
Study 38233810 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously every 3 weeks for up to 6 cycles
Number of subjects: 0
Study 38233810 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study 38233816 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin α1 (1.6 mg subcutaneous injections for 24 weeks, daily for the first 2 weeks, biweekly for the next 22 weeks)
Number of subjects: 20
Study 38233878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) at 0.07 mg/kg/day initially, adjusted by trough levels
Number of subjects: 86
Study 38233878 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) at a maximum of 2000 mg/day
Number of subjects: 86
Study 38233878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 86
Study 38233878 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 86
Study 38233878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) and Mycophenolate mofetil (MMF)
Number of subjects: 86
Study 38233885 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (2.0 g/kg every 4 weeks for 16 weeks)
Number of subjects: 95
Study 38233885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 38233885 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (1.0 g/kg in open-label extension)
Number of subjects: 95
Study 38233887 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Rotation Group (CRG) with EdgeEndo x7 rotary system
Number of subjects: 20
Study 38233887 — intervention group
Group type: COMPARATOR
Intervention: Reciprocation Group (RG) with EdgeOne Fire reciprocating system
Number of subjects: 20
Study 38233908 — intervention group
Group type: EXPERIMENTAL
Intervention: CleverCap pill bottle linked to the WiseApp (intervention)
Number of subjects: 248
Study 38233908 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 248
Study 38233983 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind urine sampling method
Number of subjects: 412
Study 38233983 — intervention group
Group type: COMPARATOR
Intervention: Randomized-response questionnaire
Number of subjects: 412
Study 38234020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (50 mg/kg/day, 100 mg/kg/day, 200 mg/kg/day) with bevacizumab (10 mg/kg/dose) and irinotecan (150 mg/m2)
Number of subjects: 10
Study 38234165 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 0
Study 38234165 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 0
Study 38234165 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 38234326 — intervention group
Group type: EXPERIMENTAL
Intervention: Venting Wisely care pathway for HRF and ARDS patients
Number of subjects: 18816
Study 38234326 — intervention group
Group type: COMPARATOR
Intervention: Preimplementation group
Number of subjects: 18816
Study 38234326 — intervention group
Group type: COMPARATOR
Intervention: Postimplementation group
Number of subjects: 18816
Study 38234368 — intervention group
Group type: EXPERIMENTAL
Intervention: DELTA intervention group
Number of subjects: 0
Study 38234368 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 38234709 — intervention group
Group type: EXPERIMENTAL
Intervention: Online recruitment via social media
Number of subjects: 60
Study 38234736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nthabi conversational agent system for family planning education
Number of subjects: 172
Study 38234736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nthabi conversational agent system for folic acid education
Number of subjects: 172
Study 38235411 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 160
Study 38235421 — intervention group
Group type: EXPERIMENTAL
Intervention: RC48 2.0 mg/kg plus toripalimab 3 mg/kg, q2w
Number of subjects: 56
Study 38235421 — intervention group
Group type: EXPERIMENTAL
Intervention: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w
Number of subjects: 56
Study 38235421 — intervention group
Group type: EXPERIMENTAL
Intervention: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w (HER2-positive population)
Number of subjects: 56
Study 38235421 — intervention group
Group type: EXPERIMENTAL
Intervention: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w (low HER2 expressing population)
Number of subjects: 56
Study 38235421 — intervention group
Group type: EXPERIMENTAL
Intervention: Other solid tumours (including breast cancer and endometrial carcinoma)
Number of subjects: 56
Study 38235512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovleplenib (600 mg q.d. for >65 kg or 400 mg q.d. for ≤65 kg)
Number of subjects: 134
Study 38235512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovleplenib (200-800 mg once daily or 200 mg twice daily)
Number of subjects: 134
Study 38235512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovleplenib (at RP2D)
Number of subjects: 134
Study 38235519 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (20 mg/m2 intravenously in cycle 1 on days 1 and 2, then 56 mg/m2 from day 8 onwards), thalidomide (100 mg orally in the evening), and dexamethasone (40 mg weekly, 20 mg for patients ≥75 years) for 18 months.
Number of subjects: 93
Study 38235519 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, thalidomide, and dexamethasone (KTd) treatment.
Number of subjects: 93
Study 38235709 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 89
Study 38235741 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-EYE-assisted colonoscopy (CAC)
Number of subjects: 1031
Study 38235741 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 1031
Study 38235741 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC
Number of subjects: 1031
Study 38235741 — intervention group
Group type: COMPARATOR
Intervention: CC
Number of subjects: 1031
Study 38235831 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D consultation
Number of subjects: 52
Study 38235831 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation
Number of subjects: 52
Study 38235907 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS placement
Number of subjects: 130
Study 38235907 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (paracentesis plus albumin 8 g/L of removed ascites)
Number of subjects: 130
Study 38235985 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient (OPT) management
Number of subjects: 97
Study 38235985 — intervention group
Group type: COMPARATOR
Intervention: Inpatient management
Number of subjects: 97
Study 38236020 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 0
Study 38236020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38236166 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 DPI (low-medium internal resistance)
Number of subjects: 76
Study 38236166 — intervention group
Group type: EXPERIMENTAL
Intervention: R5 DPI (high internal resistance)
Number of subjects: 76
Study 38236166 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical position (standing, sitting, semi-upright)
Number of subjects: 76
Study 38236223 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes (0.4 mg/g)
Number of subjects: 0
Study 38236223 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate nicotine content cigarettes (2.4 mg/g)
Number of subjects: 0
Study 38236223 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine content cigarettes (15.8 mg/g)
Number of subjects: 0
Study 38236223 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38236233 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (SA) exercise
Number of subjects: 484
Study 38236233 — intervention group
Group type: COMPARATOR
Intervention: Personalized feedback intervention (PFI)
Number of subjects: 484
Study 38236233 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 484
Study 38236249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept (2-4 mg/kg) plus pembrolizumab (2 mg/kg), administered intravenously every 2 weeks
Number of subjects: 10
Study 38236314 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 0
Study 38236314 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 0
Study 38236314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38236314 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0
Study 38236316 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPSE
Number of subjects: 152
Study 38236316 — intervention group
Group type: EXPERIMENTAL
Intervention: LV-LWFS
Number of subjects: 152
Study 38236316 — intervention group
Group type: COMPARATOR
Intervention: LVEF
Number of subjects: 152
Study 38236316 — intervention group
Group type: COMPARATOR
Intervention: s´
Number of subjects: 152
Study 38236316 — intervention group
Group type: COMPARATOR
Intervention: LVLS
Number of subjects: 152
Study 38236316 — intervention group
Group type: COMPARATOR
Intervention: OSFD
Number of subjects: 152
Study 38236316 — intervention group
Group type: COMPARATOR
Intervention: 30-day mortality
Number of subjects: 152
Study 38236365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking methods (self-report, GP report, follow-up call)
Number of subjects: 4470
Study 38236365 — intervention group
Group type: COMPARATOR
Intervention: Site reports
Number of subjects: 4470
Study 38236365 — intervention group
Group type: COMPARATOR
Intervention: Participant reports
Number of subjects: 4470
Study 38236365 — intervention group
Group type: EXPERIMENTAL
Intervention: Geofencing
Number of subjects: 4470
Study 38236409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G6 real-time continuous glucose monitoring (rtCGM)
Number of subjects: 0
Study 38236409 — intervention group
Group type: COMPARATOR
Intervention: FreeStyle Libre 1 intermittently scanned continuous glucose monitoring (isCGM)
Number of subjects: 0
Study 38236431 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide (0.5 mg and 1.0 mg)
Number of subjects: 110
Study 38236431 — intervention group
Group type: COMPARATOR
Intervention: Once-daily sitagliptin (100 mg)
Number of subjects: 110
Study 38236515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota, live-jslm (REBYOTA [RBL])
Number of subjects: 86
Study 38236515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 38236575 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice daily
Number of subjects: 45
Study 38236575 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice daily with Durvalumab 1,500 mg on day 1 every 4 weeks
Number of subjects: 45
Study 38236575 — intervention group
Group type: COMPARATOR
Intervention: Historical control of continued platinum-based therapy
Number of subjects: 45
Study 38236581 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone or Enzalutamide
Number of subjects: 118
Study 38236581 — intervention group
Group type: EXPERIMENTAL
Intervention: HOXB13 CTC detection
Number of subjects: 118
Study 38236581 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HOXB13 CTC detection
Number of subjects: 118
Study 38236590 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 1298
Study 38236590 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant
Number of subjects: 1298
Study 38236590 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole + Fulvestrant (A+F)
Number of subjects: 1298
Study 38236590 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole + Fulvestrant (A+F) in luminal B tumors
Number of subjects: 1298
Study 38236602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visitation
Number of subjects: 742
Study 38236602 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 742
Study 38236603 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation of well-reduced medial malleolus fractures (n=78)
Number of subjects: 154
Study 38236603 — intervention group
Group type: COMPARATOR
Intervention: Nonfixation of medial malleolus fractures (n=76)
Number of subjects: 154
Study 38236634 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS app (mHealth tool)
Number of subjects: 11
Study 38236638 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week self-help program delivered through a mobile app involving 7 weekly 10-minute videos
Number of subjects: 170
Study 38236638 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual condition (waitlist control)
Number of subjects: 170
Study 38236638 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week self-help program
Number of subjects: 170
Study 38236701 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version with a full bladder
Number of subjects: 70
Study 38236701 — intervention group
Group type: COMPARATOR
Intervention: External cephalic version with an empty bladder
Number of subjects: 70
Study 38236702 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum
Number of subjects: 296
Study 38236702 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant capecitabine
Number of subjects: 296
Study 38237075 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilate prophylaxis for 12 months
Number of subjects: 33
Study 38237077 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R with ixazomib (3 mg established as recommended phase 2 dose), administered for 6 cycles with ixazomib given twice per 21-day cycle; responders continued weekly ixazomib maintenance for up to 1 year.
Number of subjects: 36
Study 38237077 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R with ixazomib
Number of subjects: 36
Study 38237090 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-COVID patients
Number of subjects: 105
Study 38237090 — intervention group
Group type: COMPARATOR
Intervention: Pandemic controls
Number of subjects: 105